Ayesha Ahmar, MD
Family Medicine · Lake Mary, FLNPI 1215955000
Payments from drug & device makers
Across 270 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Amgen$757
- Medtronic$555
- Boehringer Ingelheim$493
- Novo Nordisk$469
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,521100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,091 |
| AbbVie(2 entities) | 35 | $1,002 |
| Amgen | 20 | $757 |
| Medtronic(2 entities) | 4 | $555 |
| Boehringer Ingelheim | 18 | $493 |
| Novo Nordisk | 27 | $469 |
| GSK | 16 | $404 |
| Lilly USA, LLC | 20 | $346 |
| Pfizer | 11 | $189 |
| Zimmer Biomet | 2 | $177 |
| Axsome Therapeutics, Inc. | 3 | $176 |
| Johnson & Johnson | 3 | $169 |
| Teva Pharmaceuticals USA, Inc. | 6 | $167 |
| Teleflex LLC | 1 | $162 |
| Bayer | 7 | $144 |
| Abbott | 8 | $137 |
| Merck | 8 | $118 |
| Biohaven Pharmaceuticals, Inc. | 1 | $118 |
| Exact Sciences | 5 | $105 |
| Boston Scientific | 1 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $84 |
| Dexcom, Inc. | 2 | $84 |
| Radius Health, Inc. | 2 | $84 |
| Idorsia Pharmaceuticals US Inc | 5 | $81 |
| Corcept Therapeutics | 3 | $69 |
| Kowa Pharmaceuticals America, Inc. | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Eisai Inc. | 2 | $25 |
| Biogen | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$389
- UBRELVY$323
- UroLift$162
- IN.PACT Admiral$158
- HawkOne$157
- PERCEPT PC BRAINSENSE$154
- XARELTO$134
- JARDIANCE$120
- NURTEC ODT$118
- FARXIGA$116
- AIRSUPRA$114
- Auvelity$112
- Otezla$112
- TRELEGY ELLIPTA$111
- ROSA$111
- BREZTRI$108
- AJOVY$106
- QULIPTA$105
- VRAYLAR$101
How this compares
$7,548 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $96,599 |
| FarxigaDapagliflozin Propanediol | 33 | $39,404 |
| MounjaroTirzepatide | 31 | $33,279 |
| JardianceEmpagliflozin | 32 | $31,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $19,046 |
| EliquisApixaban | 28 | $18,873 |
| ProliaDenosumab | 11 | $18,800 |
| MyrbetriqMirabegron | 18 | $9,644 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,788 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,592 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $4,589 |
| Atorvastatin Calcium | 479 | $3,525 |
| Levothyroxine Sodium | 263 | $2,263 |
| Gabapentin | 112 | $2,247 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $469 | $96,59970 claims |
| AstraZenecaFarxiga | $1,091 | $39,40433 claims |
| Lilly USA, LLCMounjaro | $346 | $33,27931 claims |
| Boehringer IngelheimJardiance | $493 | $31,30132 claims |
| GSKTrelegy Ellipta | $404 | $19,04615 claims |
| PfizerEliquis | $189 | $18,87328 claims |
| AmgenProlia | $757 | $18,80011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $2,263263 claims |
| AbbVieSynthroid | $1,002 | $1,76630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lake Mary
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.